Merck, called MSD outside of Canada and the U.S., recently announced that a representative will present new data about Zepatier (elbasvir and grazoprevir), as well as chronic hepatitis C clinical development programs, at The Liver Meeting 2016.
The presentation will include 15 scientific abstracts. Featuring seven oral and eight poster presentations, the abstracts emphasize the latest findings from Merck’s HCV clinical development programs.
Merck’s latest studies have centered around evaluations of Zepatier in 500mg and 100mg tablets. Scientists also studied Merck’s investigational MK-3682B for a variety of patients who have chronic HCV infections.
“Merck has been a part of the fight against chronic hepatitis C infection for more than 30 years, and that fight continues,” Dr. Eliav Barr, senior vice president of global clinical development, infectious diseases and vaccines at Merck Research Laboratories, said. “Chronic hepatitis C is a complex infectious disease that affects tens of millions of patients globally, each with their own personal circumstances, co-morbidities and challenges. At AASLD this year, researchers will share data from numerous studies that are underway to better understand the potential of Zepatier and our investigational medicines in diverse patient populations.”
The Liver Meeting will be held in Boston, Massachusetts, in November.
